Vanguard Group Inc. Buys 350,606 Shares of Guardant Health, Inc. (NASDAQ:GH)

Vanguard Group Inc. lifted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 3.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 12,052,551 shares of the company's stock after acquiring an additional 350,606 shares during the period. Vanguard Group Inc. owned approximately 9.75% of Guardant Health worth $368,205,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Wellington Management Group LLP grew its position in Guardant Health by 188.6% in the third quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company's stock valued at $232,325,000 after acquiring an additional 6,618,785 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of Guardant Health in the 3rd quarter worth about $15,624,000. Two Sigma Advisers LP grew its holdings in shares of Guardant Health by 52.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company's stock worth $27,007,000 after purchasing an additional 406,500 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Guardant Health by 19.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after purchasing an additional 238,037 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its holdings in Guardant Health by 15.6% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after purchasing an additional 197,729 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Stephens reaffirmed an "overweight" rating and set a $55.00 price objective on shares of Guardant Health in a report on Wednesday, March 26th. Raymond James reaffirmed an "outperform" rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Stifel Nicolaus increased their target price on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Finally, Barclays started coverage on Guardant Health in a report on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 price target for the company. Twenty research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $48.95.

Guardant Health Stock Up 3.0 %

NASDAQ GH traded up $1.20 on Monday, reaching $41.78. The company had a trading volume of 2,342,900 shares, compared to its average volume of 2,127,967. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The stock's 50 day moving average is $44.28 and its 200-day moving average is $35.07. The stock has a market cap of $5.16 billion, a price-to-earnings ratio of -11.74 and a beta of 1.45.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. As a group, analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.